Development and validation of a nomogram for predicting lymph node metastasis in early gastric cancer

Table 1 Demographic and clinicopathological data for both cohorts

Factor	Development group		Validation group
	LNM-, n = 602	LNM+, n = 148	LNM-, n = 197	LNM+, n = 53
Age in yr
≤ 60	340	88	103	38
> 60	262	60	94	15
Sex
Female	210	68	72	31
Male	392	80	125	22
BMI
≤ 24	421	100	130	36
> 24	181	48	67	17
Tumor size in cm
≤ 2	392	47	107	17
> 2	210	101	90	36
Tumor location
Proximal	66	2	17	1
Middle	96	39	31	20
Distal	440	107	149	32
Differentiation
Poor	450	136	78	40
Moderate	119	10	77	10
Well	33	2	42	3
Pathological type
AC	403	67	147	23
SRCC	199	81	50	30
CEA
Normal	566	136	179	50
Abnormal	36	12	18	3
CA125
Normal	589	143	194	52
Abnormal	13	5	3	1
CA19-9
Normal	578	140	190	52
Abnormal	24	8	7	1
CA242
Normal	589	146	191	52
Abnormal	13	2	6	1
CA72-4
Normal	549	131	177	45
Abnormal	53	17	20	8

AC: Adenocarcinoma; BMI: Body mass index; CA125: Carbohydrate antigen 125; CEA: Carcinoembryonic antigen; LNM: Lymph node metastasis; SRCC: Signet ring cell carcinoma.